Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents
This study will examine the safety and effectiveness of the antipsychotic drug olanzapine in children and adolescents with bipolar disorder or psychosis.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Developmental Pharmacokinetics of Psychotropic Drugs: Olanzapine|
- Olanzapine pharmacokinetics, safety, and effectiveness [ Time Frame: Measured over 8 weeks ] [ Designated as safety issue: Yes ]
|Study Start Date:||May 2000|
|Study Completion Date:||April 2007|
|Primary Completion Date:||April 2007 (Final data collection date for primary outcome measure)|
Numerous advancements in mental health treatment have been made over the past decade. Unfortunately, these advancements have focused on adults and have not been fully extended to children and adolescents. With limited pediatric information on the pharmacokinetics and pharmacodynamics for drugs used to treat mental health problems, psychiatrists are prescribing drugs for children using data extrapolated from adults, which may lead to potentially life-threatening results. Olanzapine is widely prescribed to treat both children and adults. This study will determine the safety and effectiveness of olanzapine in children and adolescents with mental health disorders. The study will also compare the effects of gender, development, body composition, and metabolic genotype and phenotype on how olanzapine works.
All participants will receive olanzapine for up to 8 weeks. Blood collection will occur at each weekly study visit. On Visit 1, participants will receive their first dose of olanzapine and repeated blood collection will occur every hour for 24 hours. Blood collection will be used to determine the time it takes for olanzapine to be absorbed into the body, its duration of action, the extent of its distribution in the body, the manner in which it is excreted from the body, and its effects on organs of the body.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00183612
|United States, Massachusetts|
|Belmont, Massachusetts, United States, 02478|
|Cambridge Health Alliance|
|Medford, Massachusetts, United States, 02155|
|Principal Investigator:||Louise G. Cohen, PharmD||Massachusetts General Hospital|